Zevin Asset Management’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $201K | Buy |
+3,647
| New | +$198K | 0.03% | 93 |
|
|
2022
Q4 | – | Sell |
-53,806
| Closed | -$1.58M | – | 78 |
|
|
2022
Q3 | $1.58M | Sell |
53,806
-2,154
| -4% | -$81.6K | 0.37% | 44 |
|
|
2022
Q2 | $3.04M | Buy |
55,960
+12,509
| +29% | +$691K | 0.69% | 37 |
|
|
2022
Q1 | $2.37M | Buy |
43,451
+12,701
| +41% | +$690K | 0.45% | 42 |
|
|
2021
Q4 | $1.7M | Buy |
30,750
+3,342
| +12% | +$174K | 0.31% | 45 |
|
|
2021
Q3 | $1.31M | Buy |
27,408
+4,535
| +20% | +$228K | 0.25% | 46 |
|
|
2021
Q2 | $1.14M | Buy |
22,873
+87
| +0.4% | +$4.18K | 0.23% | 47 |
|
|
2021
Q1 | $1.02M | Buy |
22,786
+3,066
| +16% | +$139K | 0.22% | 48 |
|
|
2020
Q4 | $907K | Buy |
19,720
+1,900
| +11% | +$87.3K | 0.21% | 47 |
|
|
2020
Q3 | $838K | Hold |
17,820
| – | – | 0.23% | 46 |
|
|
2020
Q2 | $909K | Buy |
17,820
+616
| +4% | +$31.6K | 0.28% | 45 |
|
|
2020
Q1 | $815K | Buy |
17,204
+567
| +3% | +$30.2K | 0.3% | 45 |
|
|
2019
Q4 | $977K | Sell |
16,637
-1,524
| -8% | -$84.8K | 0.3% | 48 |
|
|
2019
Q3 | $969K | Sell |
18,161
-3,472
| -16% | -$179K | 0.31% | 50 |
|
|
2019
Q2 | $1.08M | Sell |
21,633
-4,320
| -17% | -$217K | 0.35% | 47 |
|
|
2019
Q1 | $1.36M | Sell |
25,953
-408
| -2% | -$20.4K | 0.44% | 46 |
|
|
2018
Q4 | $1.26M | Sell |
26,361
-2,424
| -8% | -$119K | 0.46% | 46 |
|
|
2018
Q3 | $1.45M | Sell |
28,785
-160
| -0.6% | -$8.13K | 0.42% | 50 |
|
|
2018
Q2 | $1.46M | Sell |
28,945
-5,560
| -16% | -$280K | 0.44% | 51 |
|
|
2018
Q1 | $1.69M | Sell |
34,505
-20,300
| -37% | -$945K | 0.44% | 50 |
|
|
2017
Q4 | $2.43M | Buy |
54,805
+10,600
| +24% | +$490K | 0.55% | 48 |
|
|
2017
Q3 | $2.24M | Buy |
44,205
+620
| +1% | +$31.5K | 0.53% | 49 |
|
|
2017
Q2 | $2.35M | Sell |
43,585
-2,241
| -5% | -$119K | 0.59% | 44 |
|
|
2017
Q1 | $2.42M | Sell |
45,826
-13,630
| -23% | -$691K | 0.61% | 41 |
|
|
2016
Q4 | $2.86M | Buy |
59,456
+1,088
| +2% | +$53.7K | 0.75% | 37 |
|
|
2016
Q3 | $3.15M | Sell |
58,368
-4,000
| -6% | -$219K | 1.02% | 30 |
|
|
2016
Q2 | $3.38M | Buy |
62,368
+13,344
| +27% | +$703K | 0.94% | 29 |
|
|
2016
Q1 | $2.48M | Sell |
49,024
-5,880
| -11% | -$293K | 0.7% | 40 |
|
|
2015
Q4 | $2.77M | Buy |
54,904
+1,984
| +4% | +$101K | 0.73% | 39 |
|
|
2015
Q3 | $2.54M | Buy |
52,920
+1,400
| +3% | +$72.9K | 0.74% | 42 |
|
|
2015
Q2 | $2.68M | Buy |
51,520
+364
| +0.7% | +$20.5K | 0.72% | 44 |
|
|
2015
Q1 | $2.95M | Sell |
51,156
-284
| -0.6% | -$16.3K | 0.81% | 42 |
|
|
2014
Q4 | $2.75M | Buy |
+51,440
| New | +$2.88M | 0.77% | 47 |
|
Other funds holding GSK
JEST
Zevin Asset Management's GSK Position: Q1 2026 in Review
Zevin Asset Management opened a new position in GSK (GSK) in Q1 2026: 3,647 shares worth $201K. The stake represents 0.03% of the portfolio and ranks #93 among its holdings. This is a return to the name: Zevin Asset Management previously reported a position in GSK as recently as Q3 2022.
Zevin Asset Management first reported a position in GSK in Q4 2014 and has held it in 33 quarters since. The position peaked at $3.38M in Q2 2016. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.
- Zevin Asset Management held 3,647 shares of GSK worth $201K as of Q1 2026.
- GSK was a new Zevin Asset Management position in Q1 2026.
- GSK made up 0.03% of Zevin Asset Management's portfolio in Q1 2026, its #93 holding.
- Zevin Asset Management first reported a position in GSK in Q4 2014 and has held it in 33 quarters since.
- Zevin Asset Management's GSK position peaked at $3.38M in Q2 2016.
- 1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.
Based on Zevin Asset Management's 13F filing for Q1 2026, filed 7 May 2026.